uniQure N.V. (NASDAQ: NASDAQ:QURE), a gene therapy company with a market capitalization of $767 million, announced today the completion of enrollment for the first cohort in a Phase I/IIa trial of AMT-191, an investigational treatment for Fabry disease. Following a safety assessment by the Independent (LON:IOG) Data Monitoring Committee (IDMC), which found no significant safety concerns, the company has been advised to proceed with dosing the second cohort.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.